BUDGET IMPACT ANALYSIS OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB AS A TREATMENT FOR PREVIOUSLY UNTREATED LLC PATIENTS IN SPAIN

被引：0
|
作者：
Moreno, Martinez Estela [1 ]
De la Serna, Torroba Javier [2 ]
Escudero, Vilaplana Vicente [3 ]
Hernandez, Rivas Jose Angel [4 ]
Sanchez, Cuervo Marina [5 ]
Sanchez, Hernandez Raquel [6 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ Gregorio Maranon, Madrid, Spain
[4] Hosp Infanta Leonor, Madrid, Spain
[5] Hosp Ramon & Cajal, Madrid, Spain
[6] Abbvie Spain SLU, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-128
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [41] Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial
    Al-Sawaf, Othman
    Gentile, Brittany
    Devine, Jacob
    Sail, Kavita
    Tandon, Maneesh
    Fink, Anna-Maria
    Kutsch, Nadine
    Eichhorst, Barbara F.
    Fischer, Kirsten
    Hallek, Michael
    BLOOD, 2019, 134
  • [42] Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Stilgenbauer, Stephan
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Cartron, Guillaume
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Giever, Thomas A.
    Lozanski, Gerard
    Punnoose, Elizabeth A.
    Wang, Jue
    Hilger, James
    Mobasher, Mehrdad
    Salles, Gilles
    BLOOD, 2016, 128 (22)
  • [43] BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
    Bellone, M.
    Pradelli, L.
    Recchia, A.
    Caputo, A.
    Masetti, L.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [44] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
  • [45] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [46] THE BUDGET IMPACT OF VENETOCLAX PLUS OBINUTUZUMAB FOR FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN SAUDI ARABIA
    Alrajhi, A. M.
    Al-Abdulkarim, H.
    Khan, M.
    Alkhudair, N.
    Alshehri, H.
    Fasseeh, A.
    Aziz, A. Abd-El
    Elezbawy, B.
    Abaza, S.
    Ahmed, Y.
    Sheriba, A. N.
    Semida, A.
    Alnajjar, F.
    VALUE IN HEALTH, 2024, 27 (12)
  • [47] Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis
    He, Hongbo
    Wen, Xiaojia
    Zheng, Huyong
    HEMATOLOGY, 2024, 29 (01)
  • [48] Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Thuresson, Per-Olof
    Li, Jia
    Reyes, Carolina M.
    Veenstra, David
    BLOOD, 2017, 130
  • [49] Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
    Hengeveld, Paul J.
    Schilperoord-Vermeulen, Joyce
    Kolijn, P. Martijn
    Dubois, Julie M. N.
    Westerweel, Peter E.
    Kersting, Sabina
    Kater, Arnon P.
    Levin, Mark-David
    Langerak, Anton W.
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [50] IMMUNE EFFECTS INDUCED BY TREATMENT WITH OBINUTUZUMAB COMPARED WITH IBRUTINIB IN PATIENTS WITH LLC
    Pichardo Condorhuaman, L.
    Aguinaga, L.
    Peralta Benitez, R.
    Hernandez Perez, P.
    Farfan, G.
    de Gaona Lana, Ruiz E.
    Jorge del Val, L.
    Casajus Navasal, A.
    Nebot Villacampa, M. J.
    Marin Gorricho, R.
    Anton Remirez, J.
    Panizo Santos, C.
    Rabasa Baraibar, P.
    Najera Irazu, M. J.
    Feliu Sanchez, J.
    Garcia Munoz, R.
    HAEMATOLOGICA, 2018, 103 : 221 - 222
12345